120 related articles for article (PubMed ID: 29343979)
1. The influence of CYP3A5 polymorphisms on haloperidol treatment in patients with alcohol addiction.
Zastrozhin MS; Grishina EA; Ryzhikova KA; Smirnov VV; Savchenko LM; Bryun EA; Sychev DA
Pharmgenomics Pers Med; 2018; 11():1-5. PubMed ID: 29343979
[TBL] [Abstract][Full Text] [Related]
2. The correlation between CYP2D6 isoenzyme activity and haloperidol efficacy and safety profile in patients with alcohol addiction during the exacerbation of the addiction.
Sychev DA; Zastrozhin MS; Smirnov VV; Grishina EA; Savchenko LM; Bryun EA
Pharmgenomics Pers Med; 2016; 9():89-95. PubMed ID: 27695358
[TBL] [Abstract][Full Text] [Related]
3. Genotyping and phenotyping of CYP2D6 and CYP3A isoenzymes in patients with alcohol use disorder: correlation with haloperidol plasma concentration.
Sychev DA; Zastrozhin MS; Miroshnichenko II; Baymeeva NV; Smirnov VV; Grishina EA; Ryzhikova KA; Mirzaev KB; Markov DD; Skryabin VY; Snalina NE; Nosikova PG; Savchenko LM; Bryun EA
Drug Metab Pers Ther; 2017 Sep; 32(3):129-136. PubMed ID: 28787271
[TBL] [Abstract][Full Text] [Related]
4. CYP3A4 activity and haloperidol effects in alcohol addicts.
Zastrozhin MS; Smirnov VV; Sychev DA; Savchenko LM; Bryun EA; Matis OA
Int J Risk Saf Med; 2015; 27 Suppl 1():S23-4. PubMed ID: 26639694
[TBL] [Abstract][Full Text] [Related]
5. Impact of the Omics-Based Biomarkers on the Mirtazapine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder.
Zastrozhin MS; Skryabin V; Smirnov V; Zastrozhina AK; Kaverina EV; Klepikov DA; Grishina EA; Ryzhikova KA; Bure IV; Bryun EA; Sychev DA
Psychopharmacol Bull; 2021 Mar; 51(2):31-42. PubMed ID: 34092821
[TBL] [Abstract][Full Text] [Related]
6. Impact of the Omics-Based Biomarkers on the Fluvoxamine's Steady-State Concentration, Efficacy and Safety in Patients with Affective Disorders Comorbid with Alcohol Use Disorder.
Zastrozhin MS; Skryabin V; Smirnov V; Zastrozhina AK; Kaverina EV; Klepikov DA; Grishina EA; Ryzhikova KA; Bure IV; Bryun EA; Sychev DA
Psychopharmacol Bull; 2021 Jan; 51(1):69-80. PubMed ID: 33897064
[TBL] [Abstract][Full Text] [Related]
7. Relationship of the
Parkhomenko AA; Zastrozhin MS; Skryabin V; Petukhov AE; Pozdniakov SA; Ivanchenko VA; Zaytsev IA; Bure IV; Bochkov PO; Akmalova KA; Smirnov VV; Bryun EA; Sychev DA
Psychopharmacol Bull; 2023 Dec; 53(4):15-22. PubMed ID: 38076663
[TBL] [Abstract][Full Text] [Related]
8. Effects of plasma concentration of micro-RNA Mir-27b and CYP3A4*22 on equilibrium concentration of alprazolam in patients with anxiety disorders comorbid with alcohol use disorder.
Zastrozhin MS; Skryabin VY; Smirnov VV; Petukhov AE; Pankratenko EP; Zastrozhina AK; Grishina EA; Ryzhikova KA; Bure IV; Golovinskii PA; Koporov SG; Bryun EA; Sychev DA
Gene; 2020 May; 739():144513. PubMed ID: 32112986
[TBL] [Abstract][Full Text] [Related]
9. Association of
Parkhomenko AA; Zastrozhin MS; Pozdnyakov SA; Noskov VV; Zaytsev IA; Ivanchenko VA; Denisenko NP; Akmalova KA; Skryabin V; Bryun EA; Sychev DA
Psychopharmacol Bull; 2022 Oct; 52(4):52-60. PubMed ID: 36339274
[TBL] [Abstract][Full Text] [Related]
10. Relationship of
Parkhomenko AA; Zastrozhin MS; Skryabin V; Petukhov AE; Pozdniakov SA; Ivanchenko VA; Zaytsev IA; Bure IV; Bochkov PO; Akmalova KA; Smirnov VV; Bryun EA; Sychev DA
Psychopharmacol Bull; 2023 Dec; 53(4):8-14. PubMed ID: 38076668
[TBL] [Abstract][Full Text] [Related]
11. Correlation of
Parkhomenko AA; Zastrozhin MS; Skryabin V; Ivanchenko VA; Pozdniakov SA; Noskov VV; Zaytsev IA; Denisenko NP; Akmalova KA; Bryun EA; Sychev DA
Psychopharmacol Bull; 2022 Jun; 52(3):58-67. PubMed ID: 35815171
[TBL] [Abstract][Full Text] [Related]
12. Impact of CYP2D6 Polymorphism on Equilibrium Concentration of Fluoxetine in Patients Diagnosed With Major Depressive Disorder and Comorbid Alcohol Use Disorders.
Zastrozhin MS; Skryabin VY; Petukhov AE; Pankratenko EP; Grishina EA; Ryzhikova KA; Torrado MV; Shipitsyn VV; Bryun EA; Sychev DA
J Psychiatr Pract; 2021 Sep; 27(5):372-379. PubMed ID: 34529603
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic genetic polymorphisms affect adverse drug reactions of haloperidol in patients with alcohol-use disorder.
Zastrozhin MS; Brodyansky VM; Skryabin VY; Grishina EA; Ivashchenko DV; Ryzhikova KA; Savchenko LM; Kibitov AO; Bryun EA; Sychev DA
Pharmgenomics Pers Med; 2017; 10():209-215. PubMed ID: 28744152
[TBL] [Abstract][Full Text] [Related]
14. The Influence of Concentration of Micro-RNA hsa-miR-370-3p and CYP2D6*4 on Equilibrium Concentration of Mirtazapine in Patients With Major Depressive Disorder.
Zastrozhin ; Smirnov ; Petukhov ; Pankratenko ; Zastrozhina ; Grishina ; Ryzhikova ; Bure ; Skryabin ; Vlasovskih ; Bryun ; Sychev
Psychopharmacol Bull; 2020 Jul; 50(3):58-75. PubMed ID: 32733112
[TBL] [Abstract][Full Text] [Related]
15. Genotyping and phenotyping CYP3A4\CYP3A5: no association with antiplatelet effect of clopidogrel.
Mirzaev KB; Samsonova KI; Potapov PP; Andreev DA; Grishina EA; Ryzhikova KA; Sychev DA
Mol Biol Rep; 2019 Aug; 46(4):4195-4199. PubMed ID: 31102151
[TBL] [Abstract][Full Text] [Related]
16. Influence of Plasma Concentration of Hsa-Mir-370-3p and Cyp2d6*4 On Equilibrium Concentration of Phenazepam in Patients with Recurrent Depressive Disorder.
Zastrozhin MS; Efimova AV; Skryabin V; Smirnov VV; Petukhov AE; Pankratenko EP; Pozdniakov SA; Kaverina EV; Klepikov DA; Grishina EA; Ryzhikova KA; Bure IV; Bryun EA; Sychev DA
Psychopharmacol Bull; 2021 Nov; 51(4):87-104. PubMed ID: 34887601
[TBL] [Abstract][Full Text] [Related]
17. EFFECT OF CARBAMAZEPINE ON THE ACTIVITY OF CYP3A4 ISOENZYME IN PATIENTS WITH ALCOHOL ADDICTION.
Zastrozhin MS; Simirnov VV; Sychev DA; Savchenko LM; Bryun EA; Gushchina YS; Matis OA; Nechaev MO; Naumova AG
Eksp Klin Farmakol; 2016; 79(10):18-21. PubMed ID: 30085479
[TBL] [Abstract][Full Text] [Related]
18. Association between urinary 6β-hydroxycortisol/cortisol ratio and CYP3A5 genotypes in a normotensive population.
Rais N; Hussain A; Chawla YK; Kohli KK
Exp Ther Med; 2013 Feb; 5(2):527-532. PubMed ID: 23404385
[TBL] [Abstract][Full Text] [Related]
19. Using the CYP3A Activity Evaluation to Predict the Efficacy and Safety of Diazepam in Patients With Alcohol Withdrawal Syndrome.
Skryabin VY; Zastrozhin MS; Grishina EA; Ryzhikova KA; Shipitsyn VV; V Barna I; Galaktionova TE; Ivanov AV; Sorokin AS; Bryun EA; Sychev DA
J Pharm Pract; 2022 Aug; 35(4):518-523. PubMed ID: 33622083
[TBL] [Abstract][Full Text] [Related]
20. Genetic testing is superior over endogenous pharmacometabolomic markers to predict safety of haloperidol in patients with alcohol-induced psychotic disorder.
Skryabin V; Zastrozhin M; Parkhomenko A; Lauschke VM; Smirnov V; Petukhov A; Pankratenko E; Pozdnyakov S; Koporov S; Denisenko N; Akmalova K; Bryun E; Sychev D
Curr Drug Metab; 2022 Dec; ():. PubMed ID: 36579390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
